The combination of mutations in BRAF and NRAS genes within a one tumor in patients with cutaneous melanoma
https://doi.org/10.20538/1682-0363-2019-3-226-231
Abstract
The paper provides a clinical description and analysis of two melanoma cases with mutations in the BRAF and NRAS gene within one tumor. Until recently, it was believed that mutations in the BRAF and NRAS genes are exclusive and do not occur within the same tumor. Later it was revealed that these mutations can exist within one tumor, but this is still quite a rare phenomenon. Molecular genetic analysis of the tumor obtained from both patients showed a mutation in the 15 exon of the BRAF gene c.1799T>A (V600E) and exon 2 of the NRAS p.G13S gene (p.37 G>A). The expression level of non-mutant NRAS protein was different in both cases. In conclusion, so in one patient, despite the presence of a mutation in the NRAS gene, the level of expression of the non-mutant protein was absent, which can be related to possible posttranscriptional disorders in the regulation of gene expression.
Supporting agencies: This work was supported by the state assignment “Development of detection methods and identification of cKIT gene mutations based on real-time PCR and sequencing technologies for choosing personalized melanoma therapy”.
About the Authors
M. B. Aksenenko
Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-Yasenetsky (KrasSMU n.a. prof. V.F. Voyno-Yasenetsky)
Russian Federation
Russian Federation
PhD, Assistant of Professor, Department of Pathological Physiology,
1, P. Zheleznyaka Str., Krasnoyarsk, 660022
A. S. Averchuk
Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-Yasenetsky (KrasSMU n.a. prof. V.F. Voyno-Yasenetsky)
Russian Federation
Russian Federation
PhD, Assistant of Professor, Department of Pathological Physiology,
1, P. Zheleznyaka Str., Krasnoyarsk, 660022
T. G. Ruksha
Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-Yasenetsky (KrasSMU n.a. prof. V.F. Voyno-Yasenetsky)
Russian Federation
Russian Federation
DM, Head of Department of Pathophysiology,
1, P. Zheleznyaka Str., Krasnoyarsk, 660022
References
1. Sun Y., Liu W.Z., Liu T., Feng X., Yang N., Zhou H.F. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. Recept Signal Transduct. Res. 2015; 35 (6): 600–604. DOI: 10.3109/10799893.2015.1030412.
2. Palmieri G., Ombra M., Colombino M., Casula M., Sini M., Manca A., Paliogiannis P., Ascierto P.A., Cossu A. Multiple molecular pathways in melanomagenesis: Characterization of Therapeutic Targets. Front Oncol. 2015; 10 (5): 183. DoiDOI: 10.3389/fonc.2015.00183.
3. Hymowitz S.G., Malek S. Targeting the MAPK Pathway in RAS Mutant Cancers. Cold Spring Harb Perspect. Med. 2018; 8 (11). piPIIi: a031492. DOI: 10.1101/cshperspect.a031492.
4. Thomas N.E., Edmiston S.N., Orlow I., Kanetsky P.A., Luo L., Gibbs D.C., Parrish E.A., Hao H., Busam K.J., Armstrong B.K., Kricker A., Cust A.E., Anton-Culver H., Gruber S.B., Gallagher R.P., Zanetti R., Rosso S., Sacchetto L., Dwyer T., Ollila D.W, Begg C.B., Berwick M., Conway K., GEM Study Group. Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes. Invest Dermatol. 2018; 138 (11): 2398–2404. DOI: 10.1016/j.jid.2018.04.025.
5. Stones C.J., Kim J.E., Joseph W.R., Leung E., Marshall E.S., Finlay G.J., Shelling A.N., Baguley B.C. Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Front Genet. 2013; 8 (4): 66. DOI: 10.3389/fgene.2013.00066.
6. Chiappetta C., Proietti I., Soccodato V., Puggioni C., Zaralli R., Pacini L., Porta N., Skroza N., Petrozza V., Potenza C., Della Rocca C., Di Cristofano C. BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma. Appl. Immun. Mol. Morphol. 2015; 23 (3): 172–177. DOI: 10.1097/PAI.0000000000000071.
7. Etchevers H.C., Rose C., Kahle B., Vorbringer H., Fina F., Heux P., Berger I., Schwarz B., Zaffran S., Macagno N., Krengel S. Giant congenital melanocytic nevus with vascular malformation and epidermal cysts associated with a somatic activating mutation in BRAF. Pigment Cell Melanoma Res. 2018; 31 (3): 437–441. DOI: 10.1111/pcmr.12685.
8. Roh M.R., Eliades P., Gupta S., Tsao H. Genetics of Melanocytic Nevi. Pigment Cell Melanoma Res. 2015; 28 (6): 661–672. DOI: 10.1111/pcmr.12412.
9. Xia J., Jia P., Hutchinson K.E., Dahlman K.B., Johnson D., Sosman J., Pao W., Zhao Z. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clini- cal relevance. Mol. Cancer Ther. 2014; 13 (7): 1918–1928. DOI: 10.1158/1535-7163.MCT-13-0804.
10. Francis J.H., Grossniklaus H.E., Habib L.A., Marr B., Abramson D.H., Busam K.J. BRAF, NRAS, and GNAQ mutations in conjunctival melanocytic Nevi. Invest Ophthalmol. Vis. Sci. 2018; 59 (1): 117–121. DOI: 10.1167/iovs.17-22517.
11. Tímár J., Vizkeleti L., Doma V., Barbai T., Rásó E. Genetic progression of malignant melanoma. Cancer Metastasis Rev. 2016; 35 (1): 93–107. DOI: 10.1007/s10555-016-9613-5.
12. Raaijmakers M.I., Widmer D.S., Narechania A., Eichhoff O., Freiberger S.N., Wenzina J., Cheng P.F., Mihic- -Probst D., Desalle R., Dummer R.,Levesque M.P. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance. Oncotarget. 2016; 7 (47): 77163–77174. DOI: 10.18632/oncotarget.12848.
Review
For citations:
Aksenenko M.B., Averchuk A.S., Ruksha T.G. The combination of mutations in BRAF and NRAS genes within a one tumor in patients with cutaneous melanoma. Bulletin of Siberian Medicine. 2019;18(3):226-231. (In Russ.) https://doi.org/10.20538/1682-0363-2019-3-226-231
Views:
961
Email this article 